Summary 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), synthesized in this laboratory and currently in phase I clinical trial, is a low molecular weight inducer of tumour necrosis factor-α (TNF-α). Administration of DMXAA to mice with established transplantable tumours elicits rapid vascular collapse selectively in the tumour, followed by extensive haemorrhagic necrosis mediated primarily through the production of TNF-α. In this report we have investigated the synthesis of TNF-α mRNA in hepatic, splenic and tumour tissue. Coadministration of thalidomide with DMXAA increased anti-tumour activity and increased intra-tumoural TNF-α production approximately tenfold over that obtained with DMXAA alone. Thalidomide increased splenic TNF-α production slightly but significantly decreased serum and hepatic levels of TNF-α induced with DMXAA. Lipopolysaccharide (LPS) induced 300-fold higher serum TNF-α than did DMXAA at the maximum tolerated dose, but induced similar amounts of TNF-α in spleen, liver and tumour. Splenic TNF-α activity induced with LPS was slightly increased with thalidomide, but serum and liver TNF-α levels were suppressed. Thalidomide did not increase intra-tumoural TNF-α production induced with LPS, in sharp contrast to that obtained with DMXAA. While thalidomide improved the anti-tumour response to DMXAA, it had no effect on the anti-tumour action of LPS that did not induce a significant growth delay or cures against the Colon 38 tumour. The increase in the anti-tumour action by thalidomide in combination with DMXAA corresponded to an increase in intra-tumoural TNF-α production. Co-administration of thalidomide may represent a novel approach to improving selective intra-tumoural TNF-α production and anti-tumour efficacy of DMXAA.
Therapies that can selectively target the tumour vasculature represent an attractive approach to limiting the growth of tumours. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA, Figure 1 ), synthesized in this laboratory, demonstrates excellent activity against murine tumours, inducing irreversible cessation of tumour blood flow within 4 h of administration with little effect on perfusion of normal tissues (Zwi et al, 1994; Lash et al, 1998) . The ischaemia and haemorrhagic necrosis that follow provide a histological appearance similar to that of tumours treated with tumour necrosis factor-α (TNF-α) (Zwi et al, 1994) . DMXAA elevates serum TNF-α activity in a manner that correlates with the anti-tumour response (Philpott et al, 1995) , suggesting that the induction of TNF-α plays an essential role in its anti-tumour action. The anti-tumour activity and tumour blood flow effects of flavone acetic acid (FAA), a compound closely related to DMXAA, is inhibitable by antibodies to TNF-α (Mahadevan et al, 1990; Pratesi et al, 1990) , further supporting this hypothesis.
In murine systems, FAA and DMXAA exhibit similar profiles of immune modulation, cytokine induction and anti-tumour activities, with the exception that DMXAA is 12-fold more potent than FAA (Ching et al, 1991; Rewcastle et al, 1991) . However, only DMXAA up-regulates TNF-α mRNA in human cell lines (Ching et al, 1994a; Patel et al, 1997) , and induces TNF-α production in cultured human peripheral blood cells (Philpott et al, 1997) . Thus, DMXAA appears to be a superior clinical candidate to FAA in that it is more dose-potent and does not exhibit the mouse-human species preference of FAA. DMXAA is currently undergoing phase I clinical trial as a single agent.
Thalidomide, a small molecule with diverse pharmacological and biological effects, selectively inhibits TNF-α synthesis induced by lipopolysaccharide (LPS) and DMXAA . Thalidomide has attracted much interest in the treatment of leprosy (Sheskin, 1965; Sampaio et al, 1991 ), Behçet's disease (Gardner-Medwin et al, 1994) and pruritus Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid (Silva et al, 1994) , but was withdrawn from use as a sedative and anti-emetic in the 1960s because of its teratogenicity (Fabro et al, 1967) . Recent studies indicate that its immunosuppressive and anti-inflammatory effects would be beneficial to the treatment of graft-versus-host disease (Vogelsang et al, 1992; Uthoff et al, 1995) , rheumatoid arthritis (Gutierrez-Rodriguez et al, 1989) , prevention of graft rejection (Vogelsang et al, 1988; Uthoff et al, 1995) , HIV/AIDS (Makonkawkeyoon et al, 1993; Moreira et al, 1997) , sarcoidosis (Carlesimo et al, 1995) and various other inflammatory diseases (Burroughs et al, 1995) .
In experiments to determine whether suppression of serum TNF-α production by thalidomide affected the antitumour response to DMXAA, we found that, while serum TNF-α levels decreased, anti-tumour activity was unexpectedly improved . Reduction of tumour blood flow induced by DMXAA, which is thought to be mediated by TNF-α, was not reversed by thalidomide . Thalidomide analogues that were more potent than thalidomide in inhibiting DMXAA-induced serum TNF-α were also more potent in improving the anti-tumour response, indicating that the two activities were associated . Pentoxifylline, another inhibitor of TNF-α synthesis differing from thalidomide in both structure and mechanism of inhibition (Han et al, 1990; Moreira et al, 1993) , also increased the anti-tumour action of DMXAA .
Results with LPS also raise questions about the relationship between TNF-α production and anti-tumour effect. While LPS is more effective than DMXAA as an inducer of serum TNF-α, and both induce haemorrhagic necrosis of Colon 38 tumours, only DMXAA induces long tumour growth delays and cures (Ching et al, 1994b) . In this report, we consider whether TNF-α production in tissues, rather than in serum, provides an explanation of anti-tumour effects. We have combined the results of several techniques to investigate the effects of DMXAA and LPS in combination with thalidomide.
MATERIALS AND METHODS

Mice
C57B1/6 mice were purchased from the Department of Laboratory Animal Science, Otago Medical School, Dunedin, New Zealand. (C57B1/6 ϫ DBA/2)F 1 hybrid mice were bred in our animal facility and were housed under conditions of constant temperature and humidity according to institutional ethical guidelines. All mice were used between 8 and 12 weeks of age.
Materials
DMXAA, synthesized in this laboratory , was dissolved in 5% sodium bicarbonate and injected in a volume of 0.01 ml g Ϫ1 body weight. (C57B1/6 ϫ DBA/2)F 1 mice and C57B1/6 mice were treated with DMXAA at their respective optimal therapeutic dose of 30 mg kg Ϫ1 and 22.5 mg kg Ϫ1 . LPS (Escherichia coli serotype 055:B5, purchased from Sigma) was dissolved in water and injected at its maximum tolerated dose of 175 µg per 0.2 ml per mouse . (Ϫ)-Thalidomide was synthesized in this laboratory according to published methods (Casini and Ferappi, 1964) , dissolved in dimethyl sulphoxide and injected at 2.5 µl g Ϫ1 at a dose of 100 mg kg Ϫ1 .
Tumour growth inhibition assays
(C57B1/6 ϫ DBA/2)F 1 mice were implanted under anaesthesia (sodium pentobarbital, 90 mg kg Ϫ1 ) subcutaneously in the left flank with Colon 38 tumour fragments. When the tumours were approximately 4 mm in diameter (generally 7-9 days after implantation), mice were treated intraperitoneally with drug. Tumours were measured thrice weekly after treatment and tumour volumes were calculated as 0.52 a 2 ϫ b, where a and b are the minor and major axes of the tumour. The arithmetic means and standard errors were calculated for each point, including animals having zero measured tumour volume, and expressed as a fraction of the pretreatment volume. Growth delay was determined as the difference in the number of days required for the untreated, control and treated tumours to reach four times the pretreatment volume. Six mice were used for each group, and mice in which the tumour had completely disappeared were kept for at least 3 months to ensure that the tumours did not re-grow.
In situ hybridization
C57B1/6 mice with tumours approximately 6 mm in diameter were treated with DMXAA (22.5 mg kg Ϫ1 ), or LPS (175 µg per mouse) and, after 4 h, asphyxiated with nitrogen, and tissues fixed by whole body perfusion of paraformaldehyde in borate buffer. Tissues were further fixed after removal, snap-frozen in isopentane in liquid nitrogen, and cryosections (15 µM) were cut. The mounted sections were further fixed with paraformaldehyde, deproteinized using proteinase K, equilibrated in triethanolamine to block positive charges, and dehydrated with ascending concentrations of ethanol. 33 P-labelled antisense riboprobe (2 ϫ 10 7 cpm ml Ϫ1 ) in hybridization buffer (50% formamide, 0.2 M sodium chloride, 1 ϫ Denhardt's solution, 1 mM EDTA, 2 mM Tris-HCl, 0.1% dextran sulphate, 0.1 mg ml Ϫ1 tRNA, 2 mM dithiothreitol) was overlaid on the sections, cover-slipped and sealed, and hybridized overnight at 65ЊC. After hybridization, the sections were digested with RNAase (10 mg ml Ϫ1 , 30 min at 37ЊC), washed twice (5 min) with 2 ϫ standard saline citrate (SSC), once (10 min) with 1 ϫ SSC, and once (10 min) with 0.5 ϫ SSC, all at room temperature. Final high stringency washes were carried out using 0.1 ϫ SSC for 30 min at 65ЊC, followed by a final wash with 0.1 ϫ SSC (5 min at room temperature). Sections were dehydrated through ethanol plus 1 ϫ SSC, air-dried and processed for autoradiography. After 2-3 weeks the slides were developed and stained with haematoxylin and eosin. Sections of tissues from untreated mice were processed in an identical manner. The antisense murine TNF-α riboprobe was transcribed from a cDNA template encoding 700 base pairs of the murine TNF-α gene. Probes were radiolabelled using 33 P-UTP and a Riboprobe Gemini II labelling kit from Promega.
Northern analysis
Organs were excised from sacrificed mice, minced using scalpel blades, and total cellular RNA was extracted using Trizol (Gibco BRL) according to manufacturer's instructions. The RNA samples (10 µg) were fractionated by electrophoresis on a formaldehydedenaturing 1% agarose gel and transferred overnight to a nylon membrane (Hybond N ϩ , Amersham). After UV cross-linking (120 mJoule, UV-Stratalinker, Stratagene, San Diego, CA, USA), the membrane was baked (30 min, 78ЊC), and each membrane was pre-hybridized (2 h, 42ЊC) in 7 ml hybridization mix (50% formamide, 0.075 M sodium chloride, 0.05 M sodium dihydrogen phosphate, 5 mM EDTA, 0.001% polyvinyl pyrrolidone, 0.001% bovine serum albumin, 0.001% Ficoll, 0.01 mg ml Ϫ1 herring sperm DNA and 0.5% sodium dodecyl sulphate (SDS)). The cDNA to murine TNF-α mRNA was labelled with α 32 P-dCTP (Amersham) using a random priming kit (RTS Radprime DNA labelling system, Gibco BRL). Excess radioactivity was removed by elution through a G-50 Sephadex column and labelled probe (10 6 cpm ml Ϫ1 hybridization mix) was then added to the membrane and hybridized for 36 h at 42ЊC. The blots were washed twice in 2 ϫ SSC with 0.1% SDS for 10 min at 42ЊC, and finally in 0.2 ϫ SSC with 0.1% SDS for 10 min at 65ЊC. Blots were exposed to X-ray film for 1-3 days at Ϫ70ЊC. Membranes were then stripped (two washes in 300 ml 0.1 ϫ SSC with 1% SDS for 15 min at 80ЊC) and re-hybridized with probe for human β-actin to determine loading of the lanes. Intensity of signals was quantitated by laser densitometric scanning.
TNF-α determination
Blood was collected from the ocular sinus from mice anaesthetized with halothane, coagulated overnight at 4ЊC then centrifuged for 30 min at 2000 g at 4ЊC. Extractable TNF-α in spleen, liver and tumour was measured using a previously published method (Yang et al, 1994) . Tissues were excised, weighed and homogenized in α-modified minimal essential medium (2 ml) using a tissue homogenizer. Homogenates were centrifuged at 2000 g for 30 min at 4ЊC, and the supernatant was removed and centrifuged at 14 000 g for 30 min at 4ЊC before assay. TNF-α activity was measured using the standard L929 cytotoxicity assay (Hogan and Vogel, 1990; Philpott et al, 1995) . L929 cells (3 ϫ 10 4 per well) were allowed to adhere overnight to the bottom of flat-bottomed 96-well plates. The cells were then sensitized with Actinomycin D (8 µg ml Ϫ1 final concentration) for 1 h before the addition of serial dilutions of the samples to be assayed. Cell killing was assessed after 24 h by a colourimetric assay using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide as previously described (Philpott et al, 1995) . One unit of TNF-α was defined as that required to produce 50% killing of L929 cells.
RESULTS
Comparative effects of thalidomide on the anti-tumour action of DMXAA and LPS
We first investigated whether thalidomide could improve the anti-tumour action of LPS, another inducer of TNF-α, as it does with DMXAA . As shown in Figure 2 , thalidomide did not improve the response to LPS; rather the tumours in the groups receiving thalidomide only or in combination with LPS grew at a slightly faster rate than the untreated tumours. LPS induced a growth delay of 3 days, and one of the mice in the group of six was cured. By comparison, DMXAA alone induced a growth delay of 17 days and a cure rate of 83%, and in combination with thalidomide, all the mice were cured.
Effect of thalidomide on TNF-α mRNA and protein production induced by DMXAA or LPS C57B1/6 mice with Colon 38 tumours were treated with DMXAA (22.5 mg kg Ϫ1 ) or LPS (175 µg per mouse), with or without thalidomide (100 mg kg Ϫ1 ). Mice were bled, and spleen, liver and tumours excised 1-5 h after treatment. Serum was prepared from the blood samples for TNF-α measurements and organs were analysed for both TNF-α mRNA using Northern blots, and for TNF-α activity using a bioassay. DMXAA up-regulated TNF-α mRNA in spleen, liver and tumour within 1 h, with maximal activity at 2 h and declining thereafter. Co-administration of thalidomide resulted in a sustained and heightened transcription of TNF-α mRNA in the spleen and tumour, with TNF-α mRNA elevated to 5 h after treatment ( Figure 3A) . In the liver, thalidomide suppressed transcription as well as delaying the peak to 4 h ( Figure 3A) . LPS also up-regulated TNF-α mRNA in spleen, liver and tumour, and thalidomide suppressed transcription in all three tissues with no apparent alteration of the kinetics ( Figure 3B ). Thalidomide alone did not induce TNF-α mRNA in any of the tissues at 2 h (Figure 3 A, B) .
DMXAA and LPS induced TNF-α protein, as measured by bioassay, in the serum, spleen, liver and tumour (Figure 4 ). LPS induced 300-fold higher amounts of serum TNF-α than DMXAA with a peak 1 h after administration. Tissue TNF-α activity was high 1 h after LPS administration and it is possible that some of the measured TNF-α activity derived from contaminating blood since tissues were not perfused before extraction. The differential effects of thalidomide on TNF-α activity were in general more pronounced than those observed for TNF-α mRNA (Figure 4 ). In serum, spleen and liver, thalidomide delayed peak TNF-α activity following DMXAA from 2 h to 4 h and suppressed peak activity in serum and liver. TNF-α activity in the tumour increased with time after DMXAA treatment and peak activity was dramatically increased (ninefold) by thalidomide co-administration (Figure 4 ). In the case of LPS, thalidomide suppressed TNF-α responses in serum, spleen and tumour, and delayed the peak activity by 1-2 h. Thalidomide slightly increased TNF-α activity in the spleen.
Effect of thalidomide on the number of cells in the tumour expressing TNF-α mRNA after DMXAA
The increased TNF-α mRNA in tumour tissue caused by coadministration of thalidomide with DMXAA ( Figure 4 ) could result from either increased transcription or an increased proportion of responding cells. Sections of tumour were therefore taken 4 h after treatment from mice treated with DMXAA (22.5 mg kg Ϫ1 ) with or without thalidomide (100 mg kg Ϫ1 ), and cells expressing TNF-α mRNA were identified by in situ hybridization to an antisense riboprobe for TNF-α. Tumour tissue from control animals and from animals treated with thalidomide alone showed no labelling of cells. Tumour tissue from mice treated with DMXAA with or without thalidomide were both heavily labelled, but the number of labelled cells was similar ( Figure 5 ). . C57B1/6 mice with Colon 38 tumours were treated with DMXAA (22.5 mg kg Ϫ1 ) or LPS (175 µg per mouse) alone or in combination with thalidomide (100 mg kg Ϫ1 ). Tissues were excised after the times indicated and processed for Northern blot analysis of TNF-α mRNA expression. Negative controls were from untreated mice (Untr) or from mice 2 h after receiving thalidomide only (Thal). Tissues were pooled from three mice per group. The intensity of signals was quantitated, normalized by comparison with the signal for human β-actin to determine loading of the lanes, and expressed as a bar graph
DISCUSSION
We have investigated differences in TNF-α production in the tumour and systemic organs induced with LPS or DMXAA, with or without thalidomide, to obtain an explanation for why thalidomide, which suppresses the serum TNF-α response to both LPS and DMXAA, potentiates the anti-tumour activity only of DMXAA. Thalidomide increases the peak intra-tumoural TNF-α levels induced with DMXAA approximately tenfold while decreasing LPS-induced tumour TNF-α by sixfold. It also suppresses liver and serum TNF-α activity induced by LPS and DMXAA, while slightly elevating splenic TNF-α production. Thalidomide also delays the kinetics of TNF-α production from a peak in the normal tissues at 2 h to 4 h after DMXAA treatment, and from 1 h to 2 h after LPS (Figure 4) .
The TNF-α activity in tumour tissue induced after 1 h by LPS is much higher than that induced by DMXAA (Figure 4) , demonstrating that tumour-associated TNF-α per se does not correlate with anti-tumour effect. Early (1-2 h) TNF-α synthesis may be related to the induction of tumour haemorrhagic necrosis, which is common to the action of both LPS and DMXAA (Ching et al, 1994b) . On the other hand, the destruction of all tumour cells required for tumour regression may require the presence of tumour-associated TNF-α over a longer time period, as seen with DMXAA. Examination of tumours treated with a sub-therapeutic dose of DMXAA shows that co-administration of thalidomide decreases surviving tumour cells Effect of thalidomide on TNF-α activity in serum, spleen, liver and tumour taken at the indicated times from mice treated with DMXAA (DMX), DMXAA plus thalidomide (DMX ϩ Th), LPS and LPS plus thalidomide (LPS ϩ Th). A sample of same tissue used for the Northern analyses in Figure 3 was homogenized in 2 ml culture medium and the supernatants assayed for TNF-α activity. Serum obtained from the same pool of mice was also assayed for TNF-α activity. Activity was normalized to units TNF-α per gram of tissue homogenized or per ml of serum the number of cells expressing TNF-α mRNA. Rather, elevation of intra-tumoural TNF-α activity appears to be post-transcriptional, accentuated by TNF-α entrapment following vascular collapse.
The reason for the dramatic contrast in the effect of thalidomide on intra-tumoural TNF-α activity induced with LPS or DMXAA is not clear. In the tumour, DMXAA and LPS may activate different cell populations. We have obtained evidence that DMXAA activates a broader range of cells than LPS and induces the tumour cells themselves to produce TNF-α (Joseph et al, 1999) . The activity of LPS would be expected to be limited to cells such as the host macrophages that express surface receptors that bind to it. Moreover, different cell types may be differently regulated by thalidomide. Thalidomide is noted for its inhibition of TNF-α production by LPS-activated human blood monocytes in culture (Sampaio et al, 1991) , but bi-directional dose-dependent TNF-α modulation has been reported, depending on the cell type and stimulator used. Thalidomide enhanced TNF-α synthesis by the HL-60 human leukaemia cell line induced with phorbol esters, but inhibited TNF-α synthesis induced with okadaic acid in the same cell line (Miyachi et al, 1996) . While thalidomide inhibited synthesis of TNF-α in LPS-stimulated cultures of unfractionated human blood mononuclear cells, it enhanced TNF-α synthesis in cultures of THP-1 cells and in the adherent population of human blood mononuclear cells (Shannon and Sandoval, 1996) .
The mechanism by which thalidomide modulates TNF-α production is still unclear. Thalidomide selectively enhanced the degradation of TNF-α mRNA , but later work suggests that thalidomide inhibits HIV replication in macrophages through decreased binding activity of NFκB (Moreira et al, 1997) , an important transcription factor controlling activation of the TNF-α gene (Shakov et al, 1990) . As shown by photoaffinitylabelled thalidomide, thalidomide binds to α 1 -acid glycoproteins that have intrinsic anti-TNF-α activity (Turk et al, 1996) .
In addition to regulating TNF-α synthesis, thalidomide has a number of other effects that could contribute to the anti-tumour response, including modulation of T lymphocytes, alteration of pharmacokinetics and metabolism, and inhibition of angiogenesis. The anti-tumour action of DMXAA against the Colon 38 tumour is more efficient in immunocompetent hosts, indicating that host T-cell immunity is beneficial to tumour regression (Ching et al, 1992) . Although alterations to T-cell subsets by thalidomide were not observed in one study (Shannon et al, 1994) , co-stimulation of purified primary human T lymphocytes was shown in another (Haslett et al, 1998) . We are actively investigating the effects of thalidomide on the pharmacokinetics of DMXAA. Thalidomide inhibits angiogenesis (D'Amato et al, 1994) , and combination of angiogenesis antagonists with conventional anticancer agents can improve anti-tumour activity (Teicher et al, 1992) . However, inhibition of angiogenesis by thalidomide generally requires repeated administration and we have not observed any action of thalidomide, given either as single or multiple injections, on the growth of Colon 38 tumours ).
In conclusion, our results, together with those from studies on thalidomide analogues , strongly suggest that modulation of the magnitude and kinetics of intra-tumoural TNF-α production by thalidomide is the basis for its enhancement of the anti-tumour action of DMXAA. Thalidomide, because of its ability to increase anti-tumour efficacy whilst reducing serum TNF-α activity, might be considered as an adjunct to DMXAA in future clinical trials.
